Bridgebio Oncology Therapeutics, Inc. · NASDAQ:BBOT

Bridgebio Oncology Therapeutics — Investor Presentation (September 2026)

35 slides from Bridgebio Oncology Therapeutics's investor presentation, September 2026

  1. Slide 1: BBOT Next-Generation RAS-Pathway Therapeutics Corporate Update

    BBOT Next-Generation RAS-Pathway Therapeutics Corporate Update September 2026

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation is being made by BridgeBio Oncology Therapeutics, Inc. (“BBOT” or the “Company”). Certain statements included in this presentation that are not historical facts are forward-looking statements. Forward-looking statements generally are accompanied by words

  3. Slide 3: Advancing next generation RAS-pathway targeted small molecules

    Advancing next generation RAS-pathway targeted small molecules Bring hope to patients with mutant KRAS-driven malignancies Mission by translating innovative science into novel medicines KRAS is ON enabled by direct effector Selective targeting of RAS pathway blockade mechanism oncogenic drivers desi

  4. Slide 4: BBOT is developing three Phase 1 programs; all have generated clinical data

    BBOT is developing three Phase 1 programs; all three programs have generated clinical data supporting further development Program / Target Previously disclosed data Clinical achievements ▪ 65% ORR monotherapy (N=17) in 2L+ G12C inhibitor naïve NSCLC, 68% 6-mo. PFS, and 83% of patients remaining ✓ Co

  5. Slide 5: Q3 2026 summary: Strategic prioritization

    Q3 2026 corporate update summary: Strategic prioritization Allocating capital to opportunities with the highest probability of success, clear development path, and greatest potential patient benefit Strategic Focus BBO-8520 and pembrolizumab combination in 2L+ G12C inhibitor A experienced KRASG12C N

  6. Slide 6: BBO-8520 in 2L+ G12C inhibitor experienced patients in combination with pembrolizumab

    BBO-8520 in 2L+ G12C inhibitor experienced patients in combination with pembrolizumab A BBO-8520 KRASG12C (ON/OFF) inhibitor Strong early efficacy signals In G12C inhibitor experienced patients, BBO-8520 + pembrolizumab has shown 75% ORR at 500mg QD and 53% ORR across dose levels1 NSCLC ~21K Growing

  7. Slide 7: BBO-11818 and BBO-10203 combinations in KRASmut cancers

    BBO-11818 and BBO-10203 +/- standard of care combinations in KRASmut cancers B BBO-11818 Pan-KRAS(ON/OFF) inhibitor BBO-10203 RAS:PI3Kα breaker BBOT is uniquely positioned to fully inhibit MAPK and PI3Ka signaling in KRASmut tumors CRC ~40K Combination enrollment ongoing Multiple combination cohorts

  8. Slide 8: Investing in phase 1b cohorts with the greatest potential patient benefit

    BBOT is investing in phase 1b cohorts with the greatest potential patient benefit Indication Mutation Treatment Regimen Status of Combination Cohorts + pembrolizumab Enrolling A NSCLC KRASG12C BBO-8520 Monotherapy Enrollment Complete + BBO-10203 Enrolling KRASG12D/V BBO-11818 + cetuximab Enrolling C

  9. Slide 9: Data catalysts and cash runway

    BBO-11818 and BBO-10203 data catalysts planned for Q4 2026 Expanded BBO-8520 + pembrolizumab dataset in A 2L+ G12C inhibitor experienced KRASG12C NSCLC Mid-2027 Data update on BBO-11818 and BBO-10203 monotherapy Q4 2026 B BBO-11818 and BBO-10203 internal / SoC combination cohorts in CRC & PDAC Mid-2

  10. Slide 10: Strategic focus

    Strategic focus BBO-8520 + pembrolizumab A combination in 2L+ G12C inhibitor experienced KRASG12C NSCLC BBO-11818 and BBO-10203 +/- standard B of care in KRASmut cancers 10

  11. Slide 11: BBO-8520's direct ON/OFF inhibition enables improved therapeutic index

    BBO-8520’s direct ON/OFF inhibition enables improved therapeutic index BBO-8520 BBO-11818 BBO-10203 Growth factor Receptor tyrosine kinase Prevention of KRASG12C (OFF) KRASG12C Direct ON-state Improved adaptive (ON) inhibition drives therapeutic index in mechanisms of gains in potency combination wi

  12. Slide 12: 2L+ G12C inhibitor experienced KRASG12C NSCLC opportunity

    2L+ G12C inhibitor experienced KRASG12C NSCLC opportunity: Differentiated data in a growing market with high unmet need BBO-8520 BBO-11818 BBO-10203 Growing market Potential G12C OFF inhibitor approvals in 1L are expected to change SoC and create a significant G12Ci experienced 2L market Differentia

  13. Slide 13: G12C inhibitor naïve monotherapy efficacy and safety

    In G12C inhibitor naïve 2L+ monotherapy patients, efficacy and safety data continue to track in line with our prior data disclosure in January 2026, with an ORR of 63% BBO-8520 BBO-11818 BBO-10203 BBO-8520 efficacy evaluable1 G12C inhibitor naïve patients Treatment-related AEs and AEs of Interest Be

  14. Slide 14: 2L KRASG12C NSCLC may see increasing share of G12C inhibitor experienced patients

    2L KRASG12C NSCLC may see an increasing share of G12C inhibitor experienced patients with significant unmet need BBO-8520 BBO-11818 BBO-10203 Ph3 primary readout window G12C OFF inhibitor + pembrolizumab phase 3 trials in 1L KRASG12C NSCLC Individual trial readout Population / regimen 2027 2028 2029

  15. Slide 15: BBO-8520 ON/OFF potency could enable new immunogenic cell death with PD-1

    Following a suboptimal dose of a G12C OFF inhibitor in the 1L, BBO-8520 ON/OFF potency could enable new immunogenic cell death in combination with PD-1 BBO-8520 BBO-11818 BBO-10203 1. Targeted Therapeutic 2. Induction of 3. Immune Activation (Small Molecule + Anti-PD-1) Immunogenic Cell Death and Ad

  16. Slide 16: BBO-8520 + pembrolizumab 75% ORR at 500mg QD

    In the G12C inhibitor experienced setting, BBO-8520 + pembrolizumab has shown 75% ORR at 500mg QD and 53% ORR across dose levels in 2nd to 5th line patients BBO-8520 BBO-11818 BBO-10203 BBO-8520 in efficacy evaluable G12C inhibitor experienced patients1 Change in tumor burden over time1,4 Best overa

  17. Slide 17: ORR above phase 1 clinical benchmarks and standard of care

    BBO-8520 + pembrolizumab ORR reported to date is above phase 1 clinical benchmarks and standard of care in G12Ci pretreated patients BBO-8520 BBO-11818 BBO-10203 BBO-8520 + pembrolizumab vs. third-party trials of other KRASG12C inhibitors1 2L+ G12C inhibitor experienced ORR (%) 100 90 * uORR No appr

  18. Slide 18: Differentiated safety profile in 2L+ G12C inhibitor experienced patients

    BBO-8520 + pembrolizumab has shown a generally differentiated safety profile in 2L+ G12C inhibitor experienced patients BBO-8520 BBO-11818 BBO-10203 TRAEs reported in >20% patients & TRAEs of interest1 N=17 AE term All Grades Grade ≥3 Any TRAE 17 (100%) 7 (41.2%) DIARRHEA 13 (76.5%) 5 (29.4%) Combin

  19. Slide 19: BBO-8520 + pembrolizumab potential to address a $1-2B US opportunity

    BBO-8520 + pembrolizumab has the potential to address a $1-2B US opportunity BBO-8520 BBO-11818 BBO-10203 Patient flow to our target population KRASG12C metastatic NSCLC, US Today’s SoC SoC 2028+ 1L 1L pembro +/- chemo G12C OFFi + pembro +/- chemo 2L 2L+ G12Ci-experienced KRAS G12C OFF inhibitor Lum

  20. Slide 20: Strategic focus

    Strategic focus BBO-8520 + pembrolizumab A combination in 2L+ G12C inhibitor experienced KRASG12C NSCLC BBO-11818 and BBO-10203 +/- standard B of care in KRASmut cancers 20

  21. Slide 21: Mechanism of action for BBO-11818 and BBO-10203

    Mechanism of action for BBO-11818, Pan-KRAS (ON/OFF) inhibitor & BBO-10203, RAS:PI3Kα breaker BBO-8520 BBO-11818 BBO-10203 BBO-11818 Pan-KRAS(ON/OFF) inhibitor BBO-10203 RAS:PI3Kα breaker Mechanism of action Mechanism of action Growth factor Receptor tyrosine ▪ BBO-11818 is an orally ▪ Blocks bindin

  22. Slide 22: Designed to improve therapeutic index and enable unique combinations

    BBO-11818 and BBO-10203 were each designed to improve therapeutic index and enable unique combinations relative to competitor approaches BBO-8520 BBO-11818 BBO-10203 BBO-11818 BBO-10203 Pan-KRAS(ON/OFF) inhibitor RAS:PI3Kα breaker ▪ Improved tolerability and no ▪ Designed to overcome safety signific

  23. Slide 23: Each program clinically evaluated through monotherapy dose escalation

    Each program has been independently clinically evaluated through monotherapy dose escalation BBO-8520 BBO-11818 BBO-10203 BBO-11818 BBO-10203 Pan-KRAS(ON/OFF) inhibitor RAS:PI3Kα breaker Dose selection ✓ Escalation through top dose of 800mg BID complete ✓ 500mg QD selected as RDE Safety profile ✓ 2/

  24. Slide 24: KONQUER-101 and BREAKER-101 active cohorts

    BBO-8520 BBO-11818 BBO-10203 KONQUER-101 for BBO-11818 is KONQUER-101 & BREAKER-101 currently enrolling monotherapy Monotherapy & combination – active cohorts backfill and combination dose escalation KRASG12D/V BBO-11818 ▪ Escalation through 800mg BID fasted with no DLTs PDAC ▪ No significant skin t

  25. Slide 25: Designed for internal combination to enable superior activity in KRAS G12D/V tumors

    BBO-11818 and BBO-10203 were designed for internal combination to enable superior activity in KRASG12D/V tumors BBO-8520 BBO-11818 BBO-10203 BBO-10203 BBO-11818 ▪ Mutant KRAS strongly drives both the KRAS RAS:PI3Kα Breaker H/N RAS KRASG12D/V MAPK and AKT pathways ▪ In response to MAPK pathway inhibi

  26. Slide 26: Combination drives deeper tumor regression in preclinical models

    BBO-11818 in combination with BBO-10203 drives deeper tumor regression than single-agents in preclinical models BBO-8520 BBO-11818 BBO-10203 C1157 PDX C1329 PDX CAPAN-2 CDX CRC - KRASG12D CRC - KRASG12V PDAC - KRASG12V ● Vehicle (BID) ● Vehicle (BID) ● Vehicle (BID) ● BBO-10203 (100 mg/kg, QD) ● BBO

  27. Slide 27: Competitor approach: adding selective KRAS G12D inhibition to pan-RAS

    Competitor approach: Adding selective KRASG12D inhibition to pan-RAS results in improved efficacy due to deeper target coverage, but with high toxicity BBO-8520 BBO-11818 BBO-10203 G12Di improves pan-RAS efficacy via target … but the combination still sees high rates coverage… of toxicity 100% Overa

  28. Slide 28: BBOT approach: concurrent inhibition of PI3Kα and MAPK signaling

    BBOT approach: Enabling robust, concurrent, inhibition of RAS-driven PI3Ka and MAPK signaling using an orthogonal approach to competitors BBO-8520 BBO-11818 BBO-10203 No oncogenic signaling Partial oncogenic signaling More oncogenic signaling Competitor approach BBOT approach Monotherapy Pan-RAS Mon

  29. Slide 29: Combination with cetuximab without overlapping skin toxicity

    BBOT’s agents could enable combination with cetuximab without overlapping skin toxicity, which drives deep regressions in preclinical models BBO-8520 BBO-11818 BBO-10203 In vitro assay Synergy summary In vivo efficacy data CRC - KRASG12V BBO-11818 vs. daraxonrasib CRC - KRASG12D/V C1157 PDX CRC - KR

  30. Slide 30: Combinations could address significant unmet medical need in KRASmut cancers

    BBO-11818 and BBO-10203 combinations have the potential to address significant unmet medical need for patients with KRASmut cancers We are uniquely Potential to address positioned to robustly Clinical evaluation of CRC in combination inhibit MAPK and each molecule with PI3K and EGFR independently &

  31. Slide 31: Appendix

    APPENDIX BBO-11818 & BBO-10203 previously disclosed clinical data

  32. Slide 32: Initial cohorts demonstrate anti-tumor activity at predicted efficacious doses

    Initial cohorts demonstrate anti-tumor activity at predicted efficacious dose levels across tumor types and appears generally tolerable and manageable BBO-8520 BBO-11818 BBO-10203 Best overall response C1D15 (Steady State) in patients N=9 20 SD Best % change from baseline 10 600 mg BID (n=2) SD SD S

  33. Slide 33: BBO-11818 appears generally tolerable and manageable

    BBO-11818 appears generally tolerable and manageable BBO-8520 BBO-11818 BBO-10203 TRAEs reported in >1 patient Monotherapy safety data N=13 AE term All Grades Grade 1/2 Grade 3 BBO-11818 monotherapy (N=13) appears Nausea 8 7 1 generally tolerable and manageable Diarrhea 6 5 1 ▪ No DLTs ▪ TRAEs mainl

  34. Slide 34: BBO-10203 exposure achieved predicted efficacious levels

    BBO-10203 exposure achieved predicted efficacious levels with complete target engagement across all dose levels at steady-state BBO-8520 BBO-11818 BBO-10203 C1D15 (Steady State) PK in patients Day 1 target engagement by dose 750 mg QD (n=5) 500 mg QD (n=6) 300 mg QD (n=7) 150 mg QD (n=3) 750 mg QD (

  35. Slide 35: BBO-10203 demonstrated a potentially differentiated safety profile

    BBO-10203 demonstrated a potentially differentiated safety profile in heavily pretreated patients BBO-8520 BBO-11818 BBO-10203 TRAEs by Grade in >10% patients Monotherapy and combination safety profile N=32 has potential to be a key differentiator Monotherapy Trastuzumab FOLFOX/Bev compared to other

BridgeBio Oncology Therapeutics — Investor Presentation (September 2026) on 6ix